← Back to Search

Behavioural Intervention

BrightGo cognitive training for Alzheimer's Disease (TADF Trial)

N/A

Waitlist Available

Led By Grigore C. Burdea, PhD

Research Sponsored by Bright Cloud International Corp

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up for experimental group test is at 4, and 8 weeks from baseline. for cross-over controlles test is at 12 and 16 weeks from baseline.

Awards & highlights

TADF Trial Summary

This trial is testing a new device to help people with Alzheimer's disease. The device is used 5 days a week for 8 weeks, and people in the trial are also monitored with weekly calls from a clinical coordinator.

Eligible Conditions

Alzheimer's Disease
Healthy Aging

TADF Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ for experimental group test is at 4, and 8 weeks from baseline. for cross-over controlles test is at 12 and 16 weeks from baseline.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~for experimental group test is at 4, and 8 weeks from baseline. for cross-over controlles test is at 12 and 16 weeks from baseline.

This trial's timeline: 3 weeks for screening, Varies for treatment, and for experimental group test is at 4, and 8 weeks from baseline. for cross-over controlles test is at 12 and 16 weeks from baseline. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Mental Depression

Change in Cognitive executive function assessment score

Change in verbal memory as measured by Hopkins Verbal Learning Test, Revised (HVLT-R)

+3 more

Secondary outcome measures

Arm range of motion (goniometer)

Categorical verbal fluency (Animal Naming)

Change in the participant's quality of life as measured by the Quality of Life in Alzheimer's Disease Patient Version (QoL-AD)

+11 more

Other outcome measures

Biosensor measure (eye blink)

Biosensor measure (skin resistance)

Blood pressure

+6 more

TADF Trial Design

2Treatment groups

Experimental Treatment

Group I: Standard of care medication for early Alzheimer's disease and BrightGo device cognitive trainingExperimental Treatment2 Interventions

Participants randomized to the experimental group will have standard of care and 8 weeks of experimental computer-based therapy on the device. Then they will cross over in the control arm. Total participation 4 months during which they will be on Aricept 10 mg daily or Exelon 9.5 mg patch.

Group II: Standard of care medication for early Alzheimer's diseaseExperimental Treatment1 Intervention

Wait list controls will have standard of care only, before they cross over into the experimental group for BrightGo therapy. Total participation 4 months during which they will be on Aricept 10 mg daily or Exelon 9.5 mg patch.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Bright Cloud International CorpLead Sponsor

7 Previous Clinical Trials

86 Total Patients Enrolled

National Institute on Aging (NIA)NIH

1,668 Previous Clinical Trials

28,005,050 Total Patients Enrolled

Rutgers, The State University of New JerseyOTHER

429 Previous Clinical Trials

64,218 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the BrightGo cognitive training program unique or have other similar programs been trialed before?

"So far, 20 different clinical trials are still ongoing for BrightGo cognitive training. Out of these investigations, 5 are in Phase 3. Additionally, although many of the trial sites for BrightGo cognitive training are based in Hallandale Beach, Florida; there are a total of 76 locations running studies related to BrightGo cognitive training."

Answered by AI

What sort of mental disorders or illnesses can BrightGo help alleviate?

"The BrightGo cognitive training system can help patients with alzheimer's disease, alzheimer's disease (ad), and mild dementia of the alzheimer's type."

Answered by AI

What is the purpose of this clinical trial?

"The primary objective of this clinical trial is to evaluate the efficacy of a new treatment for language and executive function disorders. The trial will run for four months, and participants will be assessed at baseline, at two months, and at four months. Secondary outcome measures include the University of Pennsylvania Smell Identification Test (UPSIT), the Chedokee test of bimanual independence, and the Jebsen test of hand function."

Answered by AI

How many volunteers are currently enrolled in this research project?

"That is accurate. The information available on clinicaltrials.gov tells us that this particular trial is still looking for participants. This trial was initially posted on February 16th, 2022 and was updated most recently on April 26th, 2022. There are presently 14 spots open across 2 locations."

Answered by AI

Can people of age 55 or older participate in this research project?

"The age limit for participants in this trial are those patients who are 85 years old or younger and have already celebrated their 65th birthdays."

Answered by AI

Does this research build on previous findings?

"Currently, there are 20 ongoing clinical trials for BrightGo cognitive training in 33 cities and 9 countries. The first trial for BrightGo cognitive training was run in 2013 by Dong-A Pharmaceutical Co., Ltd. This Phase 3 drug approval stage trial involved 210 participants and completed its study in 2013. Since then, 198 more trials have been completed."

Answered by AI

Are there any participants required for this research project currently?

"Yes, this is an active clinical trial that has turned to recruitment. The listing on clinicaltrials.gov says the study was first posted on February 16th, 2022 and updated April 26th, 2022."

Answered by AI

How do I sign up for this opportunity?

"This study is recruiting 14 patients with Alzheimer's disease, between the ages of 65 and 85. Patients must meet the following criteria: Age 65 to 85;, Diagnosis of early Alzheimer's (Montreal Cognitive Assessment [MoCA] score of 19-25) [Nasreddine et al 2005]., English speakers;, Ability to actively move UE and to flex/extend fingers;, Stable on Aricept 10 mg daily intake or Exelon 9.5 mg patch medication, Able to consent;, Living in the community in Central Jersey so to facilitate researchers travel to home for system installation and/"

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Telerehabilitation Alzheimer's Disease Feasibility (TADF)

2022. "Telerehabilitation Alzheimer's Disease Feasibility (TADF)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04732182.

All > Aricept